Labrie F, et al. - Here, researchers investigate the impacts of intravaginal prasterone obtained in the three randomized clinical studies performed in postmenopausal women suffering from moderate to severe (MS) dyspareunia because of vulvovaginal atrophy (VVA). The efficacy data exhibit highly positive effects on all the symptoms and signs of vulvovaginal atrophy with no significant drug-related side effects in line with the physiology of menopause and intracrinology.